RSV vaccine study for adults 60 and older
Part of Infections clinical trials.
This trial tests a new RSV vaccine in adults aged 60 and older to see if it is safe and helps the immune system fight RSV. If you are generally healthy or have stable medical conditions without recent infections or vaccines, you may be eligible.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 60 years of age or older.
- You are generally in stable health, even if you have conditions like diabetes or high blood pressure that are well-managed.
- You have not had a lab-confirmed RSV infection in the last 6 months.
- You have not received an RSV vaccine in the past 2 years.
- You are not currently taking long-term high-dose steroids or other immune-suppressing medications.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 study tests an RSV vaccine (BLB-201) in infants and young children. It aims to see how the vaccine works and how safe it is, including in children who already have RSV antibodies or not.
This trial tests a new RSV vaccine for people aged 60 and above. RSV is a common virus that can cause serious breathing problems in older adults. The study will see if the vaccine is safe and helps protect you from RSV.
This study tests an RSV vaccine in adults aged 18 and older, especially those with chronic health issues like heart or lung disease. It aims to see how safe and effective the vaccine is at preventing RSV infections.
This study tests an experimental RSV vaccine (IN006) in healthy adults to check its safety and how well it triggers an immune response. It may help protect against respiratory syncytial virus (RSV), which can cause serious lung infections.
This study tests a new vaccine to protect against RSV (a common respiratory virus that causes cold-like illness, especially serious in older adults). The vaccine is made in laboratory cell cultures and includes an immune-boosting ingredient. Researchers want to see if it's safe and if it helps your body fight RSV infection.
This trial tests a booster dose of an experimental RSV vaccine (SCB-1019T) in healthy adults aged 60-85 who have already received the approved RSV vaccine AREXVY. The goal is to see if the booster is safe and boosts your immune system.
Hear when a new RSV Respiratory Syncytial Virus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.